Abstract: Sphingosine kinases (SphKs) are oncogenic enzymes that regulate the critical balance between ceramide and sphingosine-1-phosphate. Much effort has been dedicated to develop inhibitors against these enzymes. Naturally occurring pachastrissamine (jaspine B) and all its stereoisomers were prepared and evaluated for their inhibitory effects against SphKs. All eight stereoisomers exhibited moderate to potent inhibitory activity against SphK1 and SphK2. Inhibitory effects were profiled against protein kinase C (PKC) isoforms by in vitro experiments. Atypical PKCs (PKC and PKC) were inhibited by several pachastrissamine stereoisomers. The improved activity over N,N-dimethylsphingosine suggests that the cyclic scaffold in pachastrissamines facilitates potential favorable interactions with SphKs and PKCs.
Introduction
Sphingolipid metabolites such as ceramide (Cer), sphingosine (Sph), and sphingosine-1-phosphate (S1P) play important parts in diverse biological processes.
1 It has been reported that Cer and Sph promote apoptosis and inhibit proliferation, whereas S1P mediates cell proliferation and angiogenesis. 2, 3 The binding of S1P to a family of five specific G protein-coupled receptors termed S1PR 1-5 controls various biological functions. S1P can also regulate intracellular processes, but molecular targets are not fully defined. 4 Sphingosine kinases (SphKs), which catalyze the phosphorylation of Sph to form S1P are important lipid kinases. 5 S1P levels are mainly regulated by SphKs, S1P lyase, and S1P phosphatases ( Figure 1 ). Hitherto, two distinct isoforms of SphKs, SphK1, and SphK2, have been reported. 6, 7 SphK1 is overexpressed in various human tumors, 8 thereby impairing the efficacy of chemotherapy. 9 SphK1 inhibition by siRNA-mediated knockdown or pharmacologic inhibition induces apoptosis with elevation of the Cer/S1P ratio, 9 and increases the effectiveness of docetaxel in prostate cancer cell lines. 10 
3
SphK2 is defferent in its amino terminus and central region from SphK1. These two enzymes have different kinetic properties and tissue expression, implying that they may have distinct physiological roles. Indeed, in contrast to pro-survival SphK1, the SphK2 induces apoptosis by cytochrome c release. 11 Recent investigations revealed that a selective inhibitor of SphK2 attenuates experimental osteoarthritis. 12 Accordingly, SphKs could be promising drug targets for cancer chemotherapy and inflammatory diseases. So far, a number of sphingosine kinase inhibitors have been reported. 13 Pachastrissamine, a naturally occurring anhydrophytosphingosine derivative, was isolated from the Okinawan marine sponge, Pachastrissa sp. (Figure 2 ). 14 Pachastrissamine exhibits marked submicromolar cytotoxicity against several cancer cell lines. Delgado and co-workers reported the cytotoxicity of pachastrissamine diastereomers with a series of C-2 and C-3 stereochemistries on the tetrahydrofuran core, which were prepared via Sharpless asymmetric dihydroxylation. 15 Rao and coworkers also revealed that pachastrissamine enantiomer is less cytotoxic than pachastrissamine. 16 There has also been significant interest in the molecular mechanisms of cell death induced by pachastrissamine. Salma et al. revealed that pachastrissamine inhibits sphingomyelin synthase to increase the intracellular level of Cer, inducing apoptotic cell death by a caspase-dependent pathway. 17 However, its activity against isolated sphingolipid metabolizing enzymes has yet to be investigated. In the present study, we investigated the inhibitory activities of eight pachastrissamine stereoisomers 1-8 against SphKs in vitro ( Figure 2 ).
Results and discussion

Synthesis of pachastrissamine stereoisomers
Previously, we developed a stereoselective synthesis of four pachastrissamine diastereomers 1-4
with the 4S-configuration. 18 This synthetic route divergently provides four pachastrissamine diastereomers from S-Garner's aldehyde as a sole chiral pool. We prepared the other enantiomeric stereoisomers 5-8 using this successful approach from R-Garner's aldehyde (Scheme 1). Briefly, R- and TBAF-promoted tetrahydrofuran formation afforded the desired core scaffold that was successively deprotected with Mg and TFA to furnish 7.
The silyl ether of 18 was cleaved with TBAF in THF to give the triol 21. Selective monotosylation of the primary hydroxy group followed by base treatment afforded tetrahydrofuran
22.
The Boc group was removed with TFA to give 8.
Sphingosine kinase inhibition by pachastrissamine stereoisomers
To evaluate the SphK inhibitory activity of pachastrissamines, in vitro SphK inhibition assays were undertaken for SphK1 and SphK2 based on the partitioning of Sph and S1P using the LabChip3000 system. 21 N,N-dimethylsphingosine (DMS) was employed as a reference SphK inhibitor (Table 1) . 22 Interestingly, all of the pachastrissamine stereoisomers exhibited an inhibitory effect on both SphKs. 
Protein kinase C (PKC) inhibition by pachastrissamine stereoisomers
DMS was also reported to work as a protein kinase C (PKC) inhibitor. Hence, the bioactivity of pachastrissamine 1, and potent SphK inhibitors 7 and 8 were profiled against each PKC isoform ( Figure 3 ). Although numerous studies on Sph itself and DMS were revealed, 28, 29 little is known about its isoform selectivity. The individual PKC isoform is involved in different cellular process, 30 so the importance of the selectivity profiles of inhibitors is emphasized. For example, PKChas been implicated in epidermal growth factor (EGF)-stimulated chemotaxis of cancer cells, whereas PKC is an oncogenic protein required for the transformed growth and tumorigenesis of human cancer cells. 31 Pachastrissamines 1, 7 and 8 exerted complete inhibition of PKC and PKC at 10 Mwhereas modest inhibition against the other PKCs was observed (see the Supplementary data)
The inhibitory effects of pachastrissamine isomers at 3 M against PKC and PKC were ~50%, which were more potent than the reference DMS ( Figure 3 ). To our best knowledge, this is the first report on the Sph-based PKC inhibitors with selectivity for atypical PKC isozymes in vitro. 
Conclusions
In conclusion, we identified pachastrissamine (jaspine B) as a novel SphK1 and SphK2 inhibitor.
Several non-natural stereoisomers are more potent SphK inhibitors than the naturally occurring pachastrissamine. The distinct chiral tetrahydrofuran scaffold with accessory groups could facilitate favorable interactions with both enzymes. In addition, the inhibitory activities of these SphK inhibitors against atypical PKCs (PKC, PKC) were revealed, suggesting that SphKs and PKCs represent alternative molecular targets of pachastrissamines to induce apoptotic process. As such, these pachastrissamine stereoisomers obtained by our unique divergent synthesis could be promising leads to design sphingolipid-based kinase inhibitors. Further optimization of these inhibitors (especially for the alkyl side-chains) and investigations to elucidate the biological impact of these inhibitors are underway. 
tert-Butyl (R)-4-[(1R,2S)-1,2-Bis(tosyloxy)hexadecyl]-2,2-dimethyloxazolidine-3-carboxylate (12).
(2S,3R,4R)-4-Amino-2-tetradecyltetrahydrofuran-3-ol (6).
(S)-1-{(4R,5S)-2-Oxo-4-[(triisopropylsilyloxy)methyl]oxazolidin-5-yl}pentadecyl
Acetate ( The filtrate was concentrated under reduced pressure to give an oily residue, which was purified by flash chromatography over silica gel with n-hexane-EtOAc 
Sphingosine Kinase Assay
SphK inhibitory activities were evaluated by the off-chip mobility shift assay by the QuickScout ® service from Carna Bioscience (Kobe, Japan). SphK1(1-384) and SphK2(1-618) were expressed as N-terminal GST-fusion proteins using a baculovirus expression system. They were purified using glutathione sepharose chromatography. Each chemical in DMSO at different concentrations was diluted fourfold with reaction buffer [20 mM HEPES (pH 7.5), 0.01% Triton X-100, 2 mM DTT].
For SphK reactions, a combination of the compound, 1 M Sph, 5 mM MgCl 2 , ATP (25 M for SphK1; 600 M for SphK2) in reaction buffer (20 L) were incubated with each SphK in 384-well plates at room temperature for 1 h (n = 4). The reaction was terminated by addition of 60 L of termination buffer (Carna Biosciences). Substrate and product were separated by electrophoretic means using the LabChip3000 system. The kinase reaction was evaluated by the product ratio, which was calculated from the peak heights of the substrate (S) and product (P): [P/(P+S)].
Inhibition data were calculated by comparing with no-enzyme controls for 100% inhibition and noinhibitor reactions for 0% inhibition. IC 50 values were calculated using GraphPad Prism 4 software (GraphPad Software, Incorporated, La Jolla, CA, USA).
Protein Kinase C (PKC) Assay
PKC inhibitory activities were evaluated using the off-chip mobility shift assay by the temperature for 1 h (n = 2). The reaction was terminated by addition of 60 L of termination buffer (Carna Biosciences). Substrate and product were separated by electrophoretic means using the LabChip3000 system. The kinase reaction was evaluated by the product ratio, which was calculated from the peak heights of the substrate (S) and product (P) peptides: [P/(P+S)]. Inhibition data were calculated by comparing with no-enzyme controls for 100% inhibition and no-inhibitor reactions for 0% inhibition. Values are reported as percentages of maximum activity of PKCs from duplicate data points.
Scheme 1. Stereoselective synthesis of pachastrissamine stereoisomers 5-8.
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